Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromalCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromalCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’
PROT concentrates its R & D resources on its subsidiary StromalCel, Inc. in order to develop its portfolio of intellectual properties and global partnerships. StromalCel, Inc. hopes to apply its Intellectual property to the creation of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). The company’s efforts over the next few years will focus on bringing its technologies which include StromalCel™ to market as well as establishing global partnerships in order to enhance the development of its lead product. The Company intends to bring laboratory findings to clinical applications in an especially expedient manner. StromalCel™ is a unique product that is derived from non-related donors and has virtually no immune rejection response.
Cardiovascular Disease (CVD) includes dysfunctional conditions of the heart, arteries, and veins that supply oxygen to vital life-sustaining areas of the body like the brain, the heart itself, and other vital organs. If oxygen doesn’t arrive, the tissue or organ will die. According to the World Health Organization (WHO), CVD accounts for almost 30% of deaths worldwide. The cost of cardiovascular diseases in the United States in 2009 is estimated to be $475.3 billion, according to the American Heart Association.
For more information about this company please visit http://www.proteonomix.com/
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more). Rule 17B of the Securities Act of 1933 requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
PROTcrwe0722
